Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine

References

• Poulikakos PI, Rosen N. Mutant BRAF melanomas--dependence and resistance. Cancer Cell 2011; 19:11 - 5; http://dx.doi.org/10.1016/j.ccr.2011.01.008; PMID: 21251612
   PubMed Web of Science ®Google Scholar
• Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085 - 96; http://dx.doi.org/10.1200/JCO.2010.33.2312; PMID: 21383288
   PubMed Web of Science ®Google Scholar
• Schmidt P, Abken H. The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget 2011; 2:313 - 20; PMID: 21487158
   PubMed Web of Science ®Google Scholar
• Koomen JM, Smalley KS. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget 2011; 2:329 - 35; PMID: 21505227
   PubMed Web of Science ®Google Scholar
• Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2010; 2:35ra41; http://dx.doi.org/10.1126/scitranslmed.3000758; PMID: 20538618
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973 - 7; http://dx.doi.org/10.1038/nature09626; PMID: 21107323
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387 - 90; http://dx.doi.org/10.1038/nature10662; PMID: 22113612
   PubMed Web of Science ®Google Scholar
• Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008; 7:2876 - 83; http://dx.doi.org/10.1158/1535-7163.MCT-08-0431; PMID: 18790768
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010; 3:ra84; http://dx.doi.org/10.1126/scisignal.2001148; PMID: 21098728
   PubMed Web of Science ®Google Scholar
• Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012; 3:724; http://dx.doi.org/10.1038/ncomms1727; PMID: 22395615
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968 - 72; http://dx.doi.org/10.1038/nature09627; PMID: 21107320
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683 - 95; http://dx.doi.org/10.1016/j.ccr.2010.11.023; PMID: 21156289
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011; 71:2750 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-10-2954; PMID: 21317224
   PubMed Web of Science ®Google Scholar
• Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487:500 - 4; http://dx.doi.org/10.1038/nature11183; PMID: 22763439
   PubMed Web of Science ®Google Scholar
• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487:505 - 9; http://dx.doi.org/10.1038/nature11249; PMID: 22763448
   PubMed Web of Science ®Google Scholar
• Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, et al. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 2012; 7:e43369; http://dx.doi.org/10.1371/journal.pone.0043369; PMID: 22912864
   PubMedGoogle Scholar
• Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 2012; 488:337 - 42; http://dx.doi.org/10.1038/nature11331; PMID: 22895339
   PubMed Web of Science ®Google Scholar
• Chomel JC, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2011; 2:713 - 27; PMID: 21946665
   PubMed Web of Science ®Google Scholar
• Hochhaus A, La Rosée P, Müller MC, Ernst T, Cross NC. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 2011; 10:250 - 60; http://dx.doi.org/10.4161/cc.10.2.14537; PMID: 21220945
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Martinez P, Felip E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2011; 2:165 - 77; PMID: 21444946
   PubMed Web of Science ®Google Scholar
• Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008; 68:9375 - 83; http://dx.doi.org/10.1158/0008-5472.CAN-08-2223; PMID: 19010912
   PubMed Web of Science ®Google Scholar
• Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, et al. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011; 10:3003 - 15; http://dx.doi.org/10.4161/cc.10.17.17119; PMID: 21869603
   PubMed Web of Science ®Google Scholar
• Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010; 9:1781 - 91; http://dx.doi.org/10.4161/cc.9.9.11483; PMID: 20436278
   PubMed Web of Science ®Google Scholar
• Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, et al. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle 2010; 9:1629 - 38; http://dx.doi.org/10.4161/cc.9.8.11487; PMID: 20372086
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 2011; 226:2762 - 81; http://dx.doi.org/10.1002/jcp.22647; PMID: 21302297
   PubMed Web of Science ®Google Scholar
• Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol 2012; 40:639 - 44; PMID: 22200790
   PubMed Web of Science ®Google Scholar
• Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3:192 - 222; PMID: 21422497
   PubMedGoogle Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012; 3:954 - 87; PMID: 23006971
   PubMed Web of Science ®Google Scholar
• Qiu W, Sahin F, Iacobuzio-Donahue CA, Garcia-Carracedo D, Wang WM, Kuo CY, et al. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2011; 2:862 - 73; PMID: 22113502
   PubMed Web of Science ®Google Scholar
• Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan SE. Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget 2011; 2:435 - 47; PMID: 21646685
   PubMed Web of Science ®Google Scholar
• Anderson DH. p85 plays a critical role in controlling flux through the PI3K/PTEN signaling axis through dual regulation of both p110 (PI3K) and PTEN. Cell Cycle 2010; 9:2055 - 6; http://dx.doi.org/10.4161/cc.9.11.11926; PMID: 20505341
   PubMed Web of Science ®Google Scholar
• Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011; 2:538 - 50; PMID: 21730367
   PubMed Web of Science ®Google Scholar
• Kandouz M, Haidara K, Zhao J, Brisson ML, Batist G. The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways. Cell Cycle 2010; 9:398 - 407; http://dx.doi.org/10.4161/cc.9.2.10505; PMID: 20046096
   PubMed Web of Science ®Google Scholar
• Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011; 10:1563 - 70; http://dx.doi.org/10.4161/cc.10.10.15703; PMID: 21502814
   PubMed Web of Science ®Google Scholar
• Lehn S, Fernö M, Jirström K, Rydén L, Landberg G. A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle 2011; 10:956 - 62; http://dx.doi.org/10.4161/cc.10.6.15074; PMID: 21358261
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease. Cell Cycle 2010; 9:4607 - 15; http://dx.doi.org/10.4161/cc.9.23.13889; PMID: 21260944
   PubMed Web of Science ®Google Scholar
• Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2010; 9:4153 - 63; http://dx.doi.org/10.4161/cc.9.20.13454; PMID: 20948315
   PubMed Web of Science ®Google Scholar
• Glazer RI. A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53. Oncotarget 2010; 1:470 - 1; PMID: 21317445
   PubMed Web of Science ®Google Scholar
• Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami CP, McClintick JN, et al. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 2010; 1:405 - 22; PMID: 21311097
   PubMed Web of Science ®Google Scholar
• Napoli M, Girardini JE, Piazza S, Del Sal G. Wiring the oncogenic circuitry: Pin1 unleashes mutant p53. Oncotarget 2011; 2:654 - 6; PMID: 21926448
   PubMed Web of Science ®Google Scholar
• Harris JL, Khanna KK. BRCA1 A‐complex fine tunes repair functions of BRCA1. Aging (Albany NY) 2011; 3:461 - 3; PMID: 21805697
   PubMedGoogle Scholar
• Dever SM, Golding SE, Rosenberg E, Adams BR, Idowu MO, Quillin JM, et al. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination. Aging (Albany NY) 2011; 3:515 - 32; PMID: 21666281
   PubMedGoogle Scholar
• Poon JS, Eves R, Mak AS. Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway. Cell Cycle 2010; 9:4450 - 4; http://dx.doi.org/10.4161/cc.9.22.13936; PMID: 21084866
   PubMed Web of Science ®Google Scholar
• Fidalgo da Silva E, Ansari SB, Maimaiti J, Barnes EA, Kong-Beltran M, Donoghue DJ, et al. The tumor suppressor tuberin regulates mitotic onset through the cellular localization of cyclin B1. Cell Cycle 2011; 10:3129 - 39; http://dx.doi.org/10.4161/cc.10.18.17296; PMID: 21900748
   PubMed Web of Science ®Google Scholar
• Searle JS, Li B, Du W. Targeting Rb mutant cancers by inactivating TSC2. Oncotarget 2010; 1:228 - 32; PMID: 20706560
   PubMed Web of Science ®Google Scholar
• Gómez-Baldó L, Schmidt S, Maxwell CA, Bonifaci N, Gabaldón T, Vidalain PO, et al. TACC3-TSC2 maintains nuclear envelope structure and controls cell division. Cell Cycle 2010; 9:1143 - 55; http://dx.doi.org/10.4161/cc.9.6.11018; PMID: 20237422
   PubMed Web of Science ®Google Scholar
• Bhatia B, Nahlé Z, Kenney AM. Double trouble: when sonic hedgehog signaling meets TSC inactivation. Cell Cycle 2010; 9:456 - 9; http://dx.doi.org/10.4161/cc.9.3.10532; PMID: 20081363
   PubMed Web of Science ®Google Scholar
• Kolesnichenko M, Vogt PK. Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression. Cell Cycle 2011; 10:771 - 5; http://dx.doi.org/10.4161/cc.10.5.14829; PMID: 21311223
   PubMed Web of Science ®Google Scholar
• Campaner S, Doni M, Verrecchia A, Fagà G, Bianchi L, Amati B. Myc, Cdk2 and cellular senescence: Old players, new game. Cell Cycle 2010; 9:3655 - 61; http://dx.doi.org/10.4161/cc.9.18.13049; PMID: 20818171
   PubMed Web of Science ®Google Scholar
• Bansal R, Nikiforov MA. Pathways of oncogene-induced senescence in human melanocytic cells. Cell Cycle 2010; 9:2782 - 8; http://dx.doi.org/10.4161/cc.9.14.12251; PMID: 20676024
   PubMed Web of Science ®Google Scholar
• Miller KR, Kelley K, Tuttle R, Berberich SJ. HdmX overexpression inhibits oncogene induced cellular senescence. Cell Cycle 2010; 9:3376 - 82; http://dx.doi.org/10.4161/cc.9.16.12779; PMID: 20724842
   PubMed Web of Science ®Google Scholar
• Kosar M, Bartkova J, Hubackova S, Hodny Z, Lukas J, Bartek J. Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a). Cell Cycle 2011; 10:457 - 68; http://dx.doi.org/10.4161/cc.10.3.14707; PMID: 21248468
   PubMed Web of Science ®Google Scholar
• Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget 2011; 2:610 - 26; PMID: 21881167
   PubMed Web of Science ®Google Scholar
• Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S. microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle 2010; 9:2742 - 8; http://dx.doi.org/10.4161/cc.9.14.12248; PMID: 20647762
   PubMed Web of Science ®Google Scholar
• Mavrakis KJ, Leslie CS, Wendel HG. Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs. Cell Cycle 2011; 10:2845 - 9; http://dx.doi.org/10.4161/cc.10.17.16959; PMID: 21857153
   PubMed Web of Science ®Google Scholar
• Sayed D, Abdellatif M. AKT-ing via microRNA. Cell Cycle 2010; 9:3213 - 7; http://dx.doi.org/10.4161/cc.9.16.12634; PMID: 20814244
   PubMed Web of Science ®Google Scholar
• Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10:507 - 17; http://dx.doi.org/10.4161/cc.10.3.14754; PMID: 21270527
   PubMed Web of Science ®Google Scholar
• Ma S, Guan XY. MiRegulators in cancer stem cells of solid tumors. Cell Cycle 2011; 10:571 - 2; http://dx.doi.org/10.4161/cc.10.4.14772; PMID: 21311235
   PubMed Web of Science ®Google Scholar
• Valastyan S, Weinberg RA. miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 2010; 9:2124 - 9; http://dx.doi.org/10.4161/cc.9.11.11843; PMID: 20505365
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 2011; 10:1144 - 51; http://dx.doi.org/10.4161/cc.10.7.15210; PMID: 21368581
   PubMed Web of Science ®Google Scholar
• García JM, Silva J, Peña C, Garcia V, Rodríguez R, Cruz MA, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004; 41:117 - 24; http://dx.doi.org/10.1002/gcc.20062; PMID: 15287024
   PubMed Web of Science ®Google Scholar
• Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007; 37:389 - 96; http://dx.doi.org/10.1111/j.1872-034X.2007.00042.x; PMID: 17441812
   PubMed Web of Science ®Google Scholar
• Chang S, Sharan SK. Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1. Oncotarget 2012; 3:5 - 6; PMID: 22403740
   PubMed Web of Science ®Google Scholar
• Faber AC, Wong KK, Engelman JA. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 2010; 9:851 - 2; http://dx.doi.org/10.4161/cc.9.5.11096; PMID: 20160489
   PubMed Web of Science ®Google Scholar
• Rudloff U, Samuels Y. A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle 2010; 9:1487 - 503; http://dx.doi.org/10.4161/cc.9.8.11239; PMID: 20404484
   PubMed Web of Science ®Google Scholar
• Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011; 10:794 - 804; http://dx.doi.org/10.4161/cc.10.5.14956; PMID: 21311224
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle 2010; 9:3515 - 33; http://dx.doi.org/10.4161/cc.9.17.12928; PMID: 20855962
   PubMed Web of Science ®Google Scholar
• Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, et al. Transcriptional evidence for the “Reverse Warburg Effect” in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer’s disease, and “Neuron-Glia Metabolic Coupling”. Aging (Albany NY) 2010; 2:185 - 99; PMID: 20442453
   PubMedGoogle Scholar
• Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, et al. Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 2011; 10:1271 - 86; http://dx.doi.org/10.4161/cc.10.8.15330; PMID: 21512313
   PubMed Web of Science ®Google Scholar
• Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276:37258 - 65; http://dx.doi.org/10.1074/jbc.M106089200; PMID: 11486009
   PubMed Web of Science ®Google Scholar
• Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008; 14:6610 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-08-1136; PMID: 18927302
   PubMed Web of Science ®Google Scholar
• Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, et al. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 2009; 106:3913 - 8; http://dx.doi.org/10.1073/pnas.0810617106; PMID: 19237579
   PubMed Web of Science ®Google Scholar
• Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 2009; 8:2347 - 52; http://dx.doi.org/10.4161/cc.8.15.9224; PMID: 19571677
   PubMed Web of Science ®Google Scholar
• Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010; 288:10 - 6; http://dx.doi.org/10.1016/j.canlet.2009.05.027; PMID: 19540040
   PubMed Web of Science ®Google Scholar
• Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol 2011; 226:309 - 14; http://dx.doi.org/10.1002/jcp.22403; PMID: 20857428
   PubMed Web of Science ®Google Scholar
• Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem 2006; 281:24138 - 48; http://dx.doi.org/10.1074/jbc.M604597200; PMID: 16798734
   PubMed Web of Science ®Google Scholar
• Matsuo S, Yamazaki S, Takeshige K, Muta T. Crucial roles of binding sites for NFκB and C/EBPs in IkappaB-zeta-mediated transcriptional activation. Biochem J 2007; 405:605 - 15; http://dx.doi.org/10.1042/BJ20061797; PMID: 17447895
   PubMed Web of Science ®Google Scholar
• Roudkenar MH, Kuwahara Y, Baba T, Roushandeh AM, Ebishima S, Abe S, et al. Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J Radiat Res 2007; 48:39 - 44; http://dx.doi.org/10.1269/jrr.06057; PMID: 17229997
   PubMed Web of Science ®Google Scholar
• Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, Vascotto C, et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NFκB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci USA 2008; 105:14058 - 63; http://dx.doi.org/10.1073/pnas.0710846105; PMID: 18768801
   PubMed Web of Science ®Google Scholar
• Franklin RA, Rodriguez-Mora OG, Lahair MM, McCubrey JA. Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxid Redox Signal 2006; 8:1807 - 17; http://dx.doi.org/10.1089/ars.2006.8.1807; PMID: 16987033
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25:1064 - 79; http://dx.doi.org/10.1038/leu.2011.46; PMID: 21436840
   PubMed Web of Science ®Google Scholar
• Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011; 25:1080 - 94; http://dx.doi.org/10.1038/leu.2011.66; PMID: 21494257
   PubMed Web of Science ®Google Scholar
• Barré B, Coqueret O, Perkins ND. Regulation of activity and function of the p52 NF-κB subunit following DNA damage. Cell Cycle 2010; 9:4795 - 804; http://dx.doi.org/10.4161/cc.9.24.14245; PMID: 21131783
   PubMed Web of Science ®Google Scholar
• Melvin A, Mudie S, Rocha S. Further insights into the mechanism of hypoxia-induced NFκB. [corrected]. Cell Cycle 2011; 10:879 - 82; http://dx.doi.org/10.4161/cc.10.6.14910; PMID: 21325892
   PubMed Web of Science ®Google Scholar
• Bao G, Clifton M, Hoette TM, Mori K, Deng SX, Qiu A, et al. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol 2010; 6:602 - 9; http://dx.doi.org/10.1038/nchembio.402; PMID: 20581821
   PubMed Web of Science ®Google Scholar
• Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007; 6:1982 - 94; http://dx.doi.org/10.4161/cc.6.16.4603; PMID: 17721086
   PubMed Web of Science ®Google Scholar
• Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004; 104:2967 - 75; http://dx.doi.org/10.1182/blood-2004-05-1866; PMID: 15251988
   PubMed Web of Science ®Google Scholar
• Kovacevic Z, Richardson DR. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 2006; 27:2355 - 66; http://dx.doi.org/10.1093/carcin/bgl146; PMID: 16920733
   PubMed Web of Science ®Google Scholar
• Kovacevic Z, Fu D, Richardson DR. The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim Biophys Acta 2008; 1783:1981 - 92; http://dx.doi.org/10.1016/j.bbamcr.2008.05.016; PMID: 18582504
   PubMed Web of Science ®Google Scholar
• Assinder SJ, Dong Q, Kovacevic Z, Richardson DR. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 2009; 417:411 - 21; http://dx.doi.org/10.1042/BJ20081610; PMID: 19099539
   PubMed Web of Science ®Google Scholar
• Yu Y, Gutierrez E, Kovacevic Z, Saletta F, Obeidy P, Suryo Rahmanto Y, et al. Iron chelators for the treatment of cancer. Curr Med Chem 2012; 19:2689 - 702; http://dx.doi.org/10.2174/092986712800609706; PMID: 22455580
   PubMed Web of Science ®Google Scholar
• Buss JL, Greene BT, Turner J, Torti FM, Torti SV. Iron chelators in cancer chemotherapy. Curr Top Med Chem 2004; 4:1623 - 35; http://dx.doi.org/10.2174/1568026043387269; PMID: 15579100
   PubMed Web of Science ®Google Scholar
• Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009; 2:2; http://dx.doi.org/10.1186/1755-8794-2-2; PMID: 19133145
   PubMed Web of Science ®Google Scholar
• Sarafanov AG, Todorov TI, Centeno JA, Macias V, Gao W, Liang WM, et al. Prostate cancer outcome and tissue levels of metal ions. Prostate 2011; 71:1231 - 8; http://dx.doi.org/10.1002/pros.21339; PMID: 21271612
   PubMed Web of Science ®Google Scholar
• Guo W, Schlicht M, Kucynda T, Zhou P, Valyi-Nagy K, Kajdacsy-Balla A. Iron increases the invasiveness of prostate cancer cells in vitro: Mechanisms and inhibition by the antioxidant ebselen. Cancer Res 2012; 72; Supplement 1 http://dx.doi.org/10.1158/1538-7445.AM2012-4322
   Google Scholar
• Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, et al. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010; 9:3485 - 505; http://dx.doi.org/10.4161/cc.9.17.12721; PMID: 20861672
   PubMed Web of Science ®Google Scholar
• Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D’Angeli L, Bartoli A, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) 2010; 2:823 - 42; PMID: 21084727
   PubMedGoogle Scholar
• Brazzolotto X, Andriollo M, Guiraud P, Favier A, Moulis JM. Interactions between doxorubicin and the human iron regulatory system. Biochim Biophys Acta 2003; 1593:209 - 18; http://dx.doi.org/10.1016/S0167-4889(02)00391-9; PMID: 12581865
   PubMed Web of Science ®Google Scholar
• Davies NP, Suryo Rahmanto Y, Chitambar CR, Richardson DR. Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. J Pharmacol Exp Ther 2006; 317:153 - 62; http://dx.doi.org/10.1124/jpet.105.099044; PMID: 16373528
   PubMed Web of Science ®Google Scholar
• Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006; 103:14901 - 6; http://dx.doi.org/10.1073/pnas.0604979103; PMID: 17003122
   PubMed Web of Science ®Google Scholar
• Ganguly A, Chakraborty P, Banerjee K, Chatterjee S, Basu S, Sarkar A, et al. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Biometals 2012; 25:149 - 63; http://dx.doi.org/10.1007/s10534-011-9493-7; PMID: 21915630
   PubMed Web of Science ®Google Scholar
• Monier F, Mollier S, Guillot M, Rambeaud JJ, Morel F, Zaoui P. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas. Eur Urol 2002; 42:356 - 63; http://dx.doi.org/10.1016/S0302-2838(02)00350-0; PMID: 12361901
   PubMed Web of Science ®Google Scholar
• Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008; 14:2378 - 86; http://dx.doi.org/10.1158/1078-0432.CCR-07-1253; PMID: 18413828
   PubMed Web of Science ®Google Scholar
• Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27:5287 - 97; http://dx.doi.org/10.1200/JCO.2009.23.5556; PMID: 19738110
   PubMed Web of Science ®Google Scholar
• Schmidt C. Urine biomarkers may someday detect even distant tumors. J Natl Cancer Inst 2009; 101:8 - 10; http://dx.doi.org/10.1093/jnci/djn482; PMID: 19116386
   PubMed Web of Science ®Google Scholar
• Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, et al. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 2009; 69:8579 - 84; http://dx.doi.org/10.1158/0008-5472.CAN-09-1934; PMID: 19887608
   PubMed Web of Science ®Google Scholar
• Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 2009; 89:531 - 48; http://dx.doi.org/10.1038/labinvest.2009.17; PMID: 19308044
   PubMed Web of Science ®Google Scholar
• Sun Y, Yokoi K, Li H, Gao J, Hu L, Liu B, et al. NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. Clin Cancer Res 2011; 17:4331 - 40; http://dx.doi.org/10.1158/1078-0432.CCR-11-0226; PMID: 21622717
   PubMed Web of Science ®Google Scholar
• Fernández CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005; 11:5390 - 5; http://dx.doi.org/10.1158/1078-0432.CCR-04-2391; PMID: 16061852
   PubMed Web of Science ®Google Scholar
• Hu J, Van den Steen PE, Sang Q-X, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6:480 - 98; http://dx.doi.org/10.1038/nrd2308; PMID: 17541420
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, et al. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1998; 176:206 - 15; http://dx.doi.org/10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; PMID: 9618160
   PubMed Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13:35 - 48; http://dx.doi.org/10.1101/gad.13.1.35; PMID: 9887098
   PubMed Web of Science ®Google Scholar
• Abécassis I, Olofsson B, Schmid M, Zalcman G, Karniguian A. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res 2003; 291:363 - 76; http://dx.doi.org/10.1016/j.yexcr.2003.08.006; PMID: 14644158
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161 - 74; http://dx.doi.org/10.1038/nrc745; PMID: 11990853
   PubMed Web of Science ®Google Scholar
• Chappell WH, Abrams SL, Stadelman KM, LaHair MM, Franklin RA, Cocco L, et al. Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Adv Bio Reg 2012; 53 In press
   PubMedGoogle Scholar
• Chappell WH, Abrams SL, Montano G, Cervello M, Martelli AM, Candido S, et al. Effects of ectopic expression of NGAL on doxorubicin sensitivity. Oncotarget 2012; In press PMID: 23100449
   PubMed Web of Science ®Google Scholar
• Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008; 108:389 - 97; http://dx.doi.org/10.1007/s10549-007-9619-3; PMID: 17554627
   PubMed Web of Science ®Google Scholar
• Salzano M, Rusciano MR, Russo E, Bifulco M, Postiglione L, Vitale M. Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation. Cell Cycle 2012; 11:2100 - 6; http://dx.doi.org/10.4161/cc.20543; PMID: 22592532
   PubMed Web of Science ®Google Scholar
• Howe CJ, LaHair MM, Maxwell JA, Lee JT, Robinson PJ, Rodriguez-Mora O, et al. Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. J Biol Chem 2002; 277:30469 - 76; http://dx.doi.org/10.1074/jbc.M205036200; PMID: 12063265
   PubMed Web of Science ®Google Scholar
• Jensen TE, Rose AJ, Jørgensen SB, Brandt N, Schjerling P, Wojtaszewski JF, et al. Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. Am J Physiol Endocrinol Metab 2007; 292:E1308 - 17; http://dx.doi.org/10.1152/ajpendo.00456.2006; PMID: 17213473
   PubMed Web of Science ®Google Scholar
• Franklin RA, Rodriguez-Mora OG, Lahair MM, McCubrey JA. Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxid Redox Signal 2006; 8:1807 - 17; http://dx.doi.org/10.1089/ars.2006.8.1807; PMID: 16987033
   PubMed Web of Science ®Google Scholar
• Rodriguez-Mora OG, Lahair MM, Evans MJ, Kovacs CJ, Allison RR, Sibata CH, et al. Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biol Ther 2006; 5:1022 - 30; http://dx.doi.org/10.4161/cbt.5.8.2910; PMID: 16855386
   PubMed Web of Science ®Google Scholar
• Rodriquez-Mora OG, LaHair MM, McCubrey JA, Franklin RA. CaM-KI and CAM-KK participate in the control of cell cycle progression in MCF-7 breast cancer cells. Cancer Res 2005; 65:5408 - 16; http://dx.doi.org/10.1158/0008-5472.CAN-05-0271; PMID: 15958590
   PubMed Web of Science ®Google Scholar
• Rongo C. Epidermal growth factor and aging: a signaling molecule reveals a new eye opening function. Aging (Albany NY) 2011; 3:896 - 905; PMID: 21931179
   PubMedGoogle Scholar
• Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012; 3:236 - 60; PMID: 22470194
   PubMed Web of Science ®Google Scholar
• Ratajczak MZ, Kucia M, Liu R, Shin DM, Bryndza E, Masternak MM, et al. RasGrf1: genomic imprinting, VSELs, and aging. Aging (Albany NY) 2011; 3:692 - 7; PMID: 21765200
   PubMedGoogle Scholar
• de Magalhães JP. A role for Ras signaling in modulating mammalian aging by the GH/IGF1 axis. Aging (Albany NY) 2011; 3:336 - 7; PMID: 21512206
   PubMedGoogle Scholar
• Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, et al. PI3Kα inhibitors that inhibit metastasis. Oncotarget 2010; 1:339 - 48; PMID: 21179398
   PubMed Web of Science ®Google Scholar
• Martelli AM, Tabellini G, Ricci F, Evangelisti C, Chiarini F, Bortul R, et al. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy. Adv Enzyme Regul 2011; In press PMID: 21983557
   PubMedGoogle Scholar
• Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E, et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25:781 - 91; http://dx.doi.org/10.1038/leu.2011.20; PMID: 21331075
   PubMed Web of Science ®Google Scholar
• Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, et al. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012; 3:371 - 94; PMID: 22564882
   PubMed Web of Science ®Google Scholar
• Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, et al. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget 2012; 3:811 - 23; PMID: 22885370
   PubMed Web of Science ®Google Scholar
• Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer?. Oncotarget 2011; 2:1314 - 21; PMID: 22248929
   PubMed Web of Science ®Google Scholar
• Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget 2010; 1:530 - 43; PMID: 21317449
   PubMed Web of Science ®Google Scholar
• Zawel L. P3Kα: a driver of tumor metastasis?. Oncotarget 2010; 1:315 - 6; PMID: 21307397
   PubMed Web of Science ®Google Scholar
• Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2:833 - 49; PMID: 22064833
   PubMed Web of Science ®Google Scholar
• Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: the new kid on the PI3K block. Oncotarget 2011; 2:321 - 8; PMID: 21487159
   PubMed Web of Science ®Google Scholar
• Dbouk HA, Backer JM. A beta version of life: p110β takes center stage. Oncotarget 2010; 1:729 - 33; PMID: 21321382
   PubMed Web of Science ®Google Scholar
• Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom’s Macroglobulinemia. Oncotarget 2010; 1:578 - 82; PMID: 21317453
   PubMed Web of Science ®Google Scholar
• Peng C, Chen Y, Li D, Li S. Role of Pten in leukemia stem cells. Oncotarget 2010; 1:156 - 60; PMID: 21297225
   PubMed Web of Science ®Google Scholar
• Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH, et al. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2011; 2:1109 - 26; PMID: 22190384
   PubMed Web of Science ®Google Scholar
• Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26:2336 - 42; http://dx.doi.org/10.1038/leu.2012.136; PMID: 22614243
   PubMed Web of Science ®Google Scholar
• Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget 2012; 3:118 - 31; PMID: 22392765
   PubMed Web of Science ®Google Scholar
• Alinari L, Christian B, Baiocchi RA. Novel targeted therapies for mantle cell lymphoma. Oncotarget 2012; 3:203 - 11; PMID: 22361516
   PubMed Web of Science ®Google Scholar
• Major P. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging (Albany NY) 2011; 3:189 - 91; PMID: 21415462
   PubMedGoogle Scholar
• Aizman E, Mor A, Levy A, George J, Kloog Y. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. Oncotarget 2012; 3:144 - 57; PMID: 22323550
   PubMed Web of Science ®Google Scholar
• Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011; 2:510 - 7; PMID: 21680954
   PubMed Web of Science ®Google Scholar
• Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222 - 33; PMID: 21447859
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) 2011; 3:1130 - 41; PMID: 22246147
   PubMedGoogle Scholar
• Finkel T. Breathing lessons: Tor tackles the mitochondria. Aging (Albany NY) 2009; 1:9 - 11; PMID: 20157592
   PubMedGoogle Scholar
• Leontieva OV, Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging (Albany NY) 2011; 3:1078 - 91; PMID: 22156391
   PubMedGoogle Scholar
• Williamson DL. Normalizing a hyperactive mTOR initiates muscle growth during obesity. Aging (Albany NY) 2011; 3:83 - 4; PMID: 21386136
   PubMedGoogle Scholar
• Blagosklonny MV. Progeria, rapamycin and normal aging: recent breakthrough. Aging (Albany NY) 2011; 3:685 - 91; PMID: 21743107
   PubMedGoogle Scholar
• Panieri E, Toietta G, Mele M, Labate V, Ranieri SC, Fusco S, et al. Nutrient withdrawal rescues growth factor-deprived cells from mTOR-dependent damage. Aging (Albany NY) 2010; 2:487 - 503; PMID: 20739737
   PubMedGoogle Scholar
• Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) 2010; 2:924 - 35; PMID: 21212465
   PubMedGoogle Scholar
• Dulic V. Be quiet and you’ll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence?. Aging (Albany NY) 2011; 3:3 - 4; PMID: 21248373
   PubMedGoogle Scholar
• Schug TT. mTOR favors senescence over quiescence in p53-arrested cells. Aging (Albany NY) 2010; 2:327 - 8; PMID: 20603524
   PubMedGoogle Scholar
• Galluzzi L, Kepp O, Kroemer G. TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) 2010; 2:535 - 7; PMID: 20876940
   PubMedGoogle Scholar
• Zhao C, Vollrath D. mTOR pathway activation in age-related retinal disease. Aging (Albany NY) 2011; 3:346 - 7; PMID: 21483039
   PubMedGoogle Scholar
• Blagosklonny MV. Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives. Aging (Albany NY) 2010; 2:265 - 73; PMID: 20519781
   PubMedGoogle Scholar
• Blagosklonny MV. Why human lifespan is rapidly increasing: solving “longevity riddle” with “revealed-slow-aging” hypothesis. Aging (Albany NY) 2010; 2:177 - 82; PMID: 20404395
   PubMedGoogle Scholar
• Maki CG. Decision-making by p53 and mTOR. Aging (Albany NY) 2010; 2:324 - 6; PMID: 20603526
   PubMedGoogle Scholar
• Rosner M, Hengstschläger M. mTOR protein localization is cell cycle-regulated. Cell Cycle 2011; 10:3608 - 10; http://dx.doi.org/10.4161/cc.10.20.17855; PMID: 22024924
   PubMed Web of Science ®Google Scholar
• Jiang Y. mTOR goes to the nucleus. Cell Cycle 2010; 9:868; http://dx.doi.org/10.4161/cc.9.5.11070; PMID: 20348849
   PubMed Web of Science ®Google Scholar
• Lisse TS, Hewison M. Vitamin D: a new player in the world of mTOR signaling. Cell Cycle 2011; 10:1888 - 9; http://dx.doi.org/10.4161/cc.10.12.15620; PMID: 21558808
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 2010; 9:683 - 8; http://dx.doi.org/10.4161/cc.9.4.10766; PMID: 20139716
   PubMed Web of Science ®Google Scholar
• Armour SM, Baur JA, Hsieh SN, Land-Bracha A, Thomas SM, Sinclair DA. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 2009; 1:515 - 28; PMID: 20157535
   PubMedGoogle Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: Targeting these pathways for cancer treatment and overcoming therapy resistance. Oncotarget 2012; In press
   Google Scholar
• Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012; 26:91 - 100; http://dx.doi.org/10.1038/leu.2011.269; PMID: 21968881
   PubMed Web of Science ®Google Scholar
• Mancias JD, Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget 2011; 2:1302 - 6; PMID: 22185891
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010; 9:3807 - 14; http://dx.doi.org/10.4161/cc.9.18.13131; PMID: 20890129
   PubMed Web of Science ®Google Scholar
• Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9:563 - 75; http://dx.doi.org/10.1038/nrc2676; PMID: 19629071
   PubMed Web of Science ®Google Scholar
• van der Velden YU, Haramis AP. Insights from model organisms on the functions of the tumor suppressor protein LKB1: zebrafish chips in. Aging (Albany NY) 2011; 3:363 - 7; PMID: 21721170
   PubMedGoogle Scholar
• Martelli AM, Chiarini F, Evangelisti C, Ognibene A, Bressanin D, Billi AM, et al. Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opin Ther Targets 2012; 16:729 - 42; http://dx.doi.org/10.1517/14728222.2012.694869; PMID: 22686561
   PubMed Web of Science ®Google Scholar
• Vakana E, Platanias LC. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget 2011; 2:1322 - 8; PMID: 22249159
   PubMed Web of Science ®Google Scholar
• Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S. microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle 2010; 9:2742 - 8; http://dx.doi.org/10.4161/cc.9.14.12248; PMID: 20647762
   PubMed Web of Science ®Google Scholar
• Chen V, Shtivelman E. CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation. Cell Cycle 2010; 9:4941 - 53; http://dx.doi.org/10.4161/cc.9.24.14230; PMID: 21150275
   PubMed Web of Science ®Google Scholar
• Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9:1091 - 6; http://dx.doi.org/10.4161/cc.9.6.11035; PMID: 20190568
   PubMed Web of Science ®Google Scholar
• Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle 2010; 9:211 - 2; http://dx.doi.org/10.4161/cc.9.2.10540; PMID: 20023392
   PubMed Web of Science ®Google Scholar
• Saha AK, Xu XJ, Balon TW, Brandon A, Kraegen EW, Ruderman NB. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation?. Cell Cycle 2011; 10:3447 - 51; http://dx.doi.org/10.4161/cc.10.20.17886; PMID: 22067655
   PubMed Web of Science ®Google Scholar
• Amato S, Man HY. Bioenergy sensing in the brain: the role of AMP-activated protein kinase in neuronal metabolism, development and neurological diseases. Cell Cycle 2011; 10:3452 - 60; http://dx.doi.org/10.4161/cc.10.20.17953; PMID: 22067656
   PubMed Web of Science ®Google Scholar
• Mounier R, Lantier L, Leclerc J, Sotiropoulos A, Foretz M, Viollet B. Antagonistic control of muscle cell size by AMPK and mTORC1. Cell Cycle 2011; 10:2640 - 6; http://dx.doi.org/10.4161/cc.10.16.17102; PMID: 21799304
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. Cell Cycle 2011; 10:1295 - 302; http://dx.doi.org/10.4161/cc.10.8.15342; PMID: 21474997
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3:148 - 57; PMID: 21386129
   PubMedGoogle Scholar
• Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896 - 917; PMID: 22203527
   PubMed Web of Science ®Google Scholar
• Menendez JA, Cufí S, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Vellon L, et al. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY) 2011; 3:1063 - 77; PMID: 22170748
   PubMedGoogle Scholar
• Halicka HD, Zhao H, Li J, Traganos F, Zhang S, Lee M, et al. Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. Aging (Albany NY) 2011; 3:1028 - 38; PMID: 22067284
   PubMedGoogle Scholar
• Gomes AP, Duarte FV, Nunes P, Hubbard BP, Teodoro JS, Varela AT, et al. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim Biophys Acta 2012; 1822:185 - 95; http://dx.doi.org/10.1016/j.bbadis.2011.10.008; PMID: 22027215
   PubMed Web of Science ®Google Scholar
• Zhao HL, Sui Y, Qiao CF, Yip KY, Leung RK, Tsui SK, et al. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes 2012; 61:933 - 43; http://dx.doi.org/10.2337/db11-1164; PMID: 22396199
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol 2012; 83:385 - 94; http://dx.doi.org/10.1016/j.bcp.2011.11.008; PMID: 22120676
   PubMed Web of Science ®Google Scholar
• Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30:214 - 26; http://dx.doi.org/10.1016/j.molcel.2008.03.003; PMID: 18439900
   PubMed Web of Science ®Google Scholar
• Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7:e33411; http://dx.doi.org/10.1371/journal.pone.0033411; PMID: 22448244
   PubMed Web of Science ®Google Scholar
• Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896 - 917; PMID: 22203527
   PubMed Web of Science ®Google Scholar
• Richardson AD, Scott DA. Reversing the Warburg effect through stromal autophagy. Cell Cycle 2011; 10:2830 - 1; http://dx.doi.org/10.4161/cc.10.17.16576; PMID: 21869600
   PubMed Web of Science ®Google Scholar
• Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D’Angeli L, Bartoli A, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) 2010; 2:823 - 42; PMID: 21084727
   PubMedGoogle Scholar
• Darnell JE Jr.. STAT3, HIF-1, glucose addiction and Warburg effect. Aging (Albany NY) 2010; 2:890 - 1; PMID: 21149895
   PubMedGoogle Scholar
• Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010; 9:4461 - 8; http://dx.doi.org/10.4161/cc.9.22.14048; PMID: 21088486
   PubMed Web of Science ®Google Scholar
• Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D, Tamburini J. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle 2011; 10:2115 - 20; http://dx.doi.org/10.4161/cc.10.13.16244; PMID: 21572254
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA. Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response. Cell Cycle 2011; 10:1499 - 501; http://dx.doi.org/10.4161/cc.10.9.15423; PMID: 21566461
   PubMed Web of Science ®Google Scholar
• Mashhedi H, Blouin MJ, Zakikhani M, David S, Zhao Y, Bazile M, et al. Metformin abolishes increased tumor (18)F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. Cell Cycle 2011; 10:2770 - 8; http://dx.doi.org/10.4161/cc.10.16.16219; PMID: 21811094
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 2011; 10:1144 - 51; http://dx.doi.org/10.4161/cc.10.7.15210; PMID: 21368581
   PubMed Web of Science ®Google Scholar
• Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9:1057 - 64; http://dx.doi.org/10.4161/cc.9.6.10994; PMID: 20305377
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9:188 - 97; http://dx.doi.org/10.4161/cc.9.1.10407; PMID: 20016287
   PubMed Web of Science ®Google Scholar